ARTICLE | Distillery Therapeutics
Therapeutics: Receptor-interacting serine-threonine kinase 3 (RIPK3; RIP3); mixed-lineage kinase domain-like (MLKL)
March 3, 2016 8:00 AM UTC
Cell and mouse studies suggest inhibiting RIPK3 or MLKL could help treat crystal-induced acute kidney injury (AKI). In mouse kidney epithelial cells, siRNA targeting RIPK3 or MLKL decreased cell death...